Immune Thombocytopenic Purpura (ITP) - Pipeline Review, H2 2011

Global Markets Direct, August 2011, Pages: 79

Immune Thombocytopenic Purpura (ITP) - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Immune Thombocytopenic Purpura (ITP) - Pipeline Review, H2 2011', provides an overview of the Immune Thombocytopenic Purpura (ITP) therapeutic pipeline. This report provides information on the therapeutic development for Immune Thombocytopenic Purpura (ITP), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Immune Thombocytopenic Purpura (ITP). 'Immune Thombocytopenic Purpura (ITP) - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Immune Thombocytopenic Purpura (ITP).
- A review of the Immune Thombocytopenic Purpura (ITP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Immune Thombocytopenic Purpura (ITP) pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Immune Thombocytopenic Purpura (ITP).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Immune Thombocytopenic Purpura (ITP) pipeline depth and focus of Immune Thombocytopenic Purpura (ITP) therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Immune Thombocytopenic Purpura (ITP) Overview
Therapeutics Development
An Overview of Pipeline Products for Immune Thombocytopenic Purpura (ITP)
Immune Thombocytopenic Purpura (ITP) Therapeutics under Development by Companies
Immune Thombocytopenic Purpura (ITP) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Immune Thombocytopenic Purpura (ITP) Therapeutics - Products under Development by Companies
Immune Thombocytopenic Purpura (ITP) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Immune Thombocytopenic Purpura (ITP) Therapeutics Development
AstraZeneca PLC
GlaxoSmithKline plc
Symphogen A/S
Eisai Co., Ltd.
IMMUNOMEDICS, INC
Maywufa Company Limited
Trillium Therapeutics Inc.
Bio Products Laboratory
SuppreMol GmbH
Immune Thombocytopenic Purpura (ITP) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Veltuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
E5501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sym001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LGD-4665 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TTI-314 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alemtuzumab + Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PHN011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PHN012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PHN013 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan + Cyclophosphamide + Vincristine + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituxan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + MabThera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gammaplex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
R788 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab + Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Daclizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SM101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rituximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IVIG + Methylprednisolone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anti-D - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IGIV3I Grifols - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Immune Thombocytopenic Purpura (ITP) Therapeutics – Drug Profile Updates
Immune Thombocytopenic Purpura (ITP) Therapeutics - Discontinued Products
Immune Thombocytopenic Purpura (ITP) - Featured News
Jul 22, 2011: GlaxoSmithKline Announces Launch Of Revolade Tablets
Jun 10, 2011: Symphogen Presents Preliminary Results From Phase II Clinical Trial With Rozrolimupab At Annual European Hematology Association
May 31, 2011: European Commission Adopts EMA's Recommendation To Lift Suspension Of Marketing Authorization Of Octagam And Octagam10%
Mar 16, 2011: NICE Gives Green Light To Romiplostim In Chronic Immune Thrombocytopenic Purpura
Feb 25, 2011: GlaxoSmithKline Receives FDA Approval For PROMACTA For Treatment Of Rare Blood Disorder
Jan 25, 2011: GSK Receives Health Canada Approval For Revolade In Chronic Immune Thrombocytopenic Purpura
Jan 24, 2011: SuppreMol Completes Successful Pre-IND Meeting With FDA For Lead Compound SM101
Dec 05, 2010: Amgen's Nplate Maintains Platelet Counts For More Than Five Years In Adults With Chronic Idiopathic Thrombocytopenic Purpura
Nov 10, 2010: Amgen Announces Publication Of Chronic ITP Study With Nplate In New England Journal Of Medicine
Nov 02, 2010: Ligand Announces Approval Of Revolade In Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Immune Thombocytopenic Purpura (ITP), H2 2011
Products under Development for Immune Thombocytopenic Purpura (ITP) – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
AstraZeneca PLC, 2011
GlaxoSmithKline plc, 2011
Symphogen A/S, 2011
Eisai Co., Ltd., 2011
IMMUNOMEDICS, INC, 2011
Maywufa Company Limited, 2011
Trillium Therapeutics Inc., 2011
Bio Products Laboratory, 2011
SuppreMol GmbH, 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Immune Thombocytopenic Purpura (ITP) Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Immune Thombocytopenic Purpura (ITP), H2 2011
Products under Development for Immune Thombocytopenic Purpura (ITP) – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Pandemic Influenza – Pipeline Review, H1 2013
• Substance (Drug) Abuse – Pipeline Review, H1 2013
• Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Potentially Supplemented by Approvals for Alzheimer’s Disease
• Nausea – Pipeline Review, H1 2013
• Brain Tumor – Pipeline Review, H1 2013
• Smoking Cessation – Pipeline Review, H1 2013
• Bone Disorders – Pipeline Review, H1 2013
• Drug Addiction – Pipeline Review, H1 2013
• Down Syndrome – Pipeline Review, H1 2013
• HIV / AIDS – Pipeline Review, H1 2013